DIAGNOSTIC MIRNAS FOR DIFFERENTIAL DIAGNOSIS OF INCIDENTAL PANCREATIC CYSTIC LESIONS
Embodiments concern methods and compositions for characterizing or evaluating neoplastic pancreatic cells using miRNAs that are measured and used in calculations to determine a risk score for a patient.
1 . A method for evaluating pancreatic neoplastic cells in a biological sample from a patient who has been determined to have pancreatic neoplastic cells comprising:
a) determining from the biological sample the levels of expression of at least miR-202-3p, miR-483-5p, miR-31-5p, and miR-192-5p; and,
b) calculating a risk score for the biological sample that identifies the sample as containing pancreatic cells that are characterized as mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof.
2 - 6 . (canceled)
7 . The method of claim 1 , wherein calculating a risk score comprises applying model coefficients to each of the levels of expression.
8 . The method of claim 7 , wherein the model coefficients were determined using logistic regression modeling, linear discriminant analysis, quadratic discriminant analysis, neural network, support vector machine, k-nearest neighbor classifier, or a variation thereof.
9 - 15 . (canceled)
16 . The method of claim 1 , further comprising measuring the level of expression of at least one of miR-708-5p, miR-21-5p, miR-375, miR-210, miR-99a-5p, miR-485-3p, miR-10b-5p, miR-337-5p, or, miR-130b-3p.
17 . (canceled)
18 . The method of claims 17 , wherein the expression of at least three of miR-708-5p, miR-21-5p, miR-375, miR-210, miR-99a-5p, miR-485-3p, miR-10b-5p, miR-337-5p, or, miR-130b-3p is measured.
19 . The method of claim 18 , wherein the expression of all of miR-708-5p, miR-21-5p, miR-375, miR-210, miR-99a-5p, miR-485-3p, miR-10b-5p, miR-337-5p, or, miR-130b-3p is measured.
20 - 24 . (canceled)
25 . A method for evaluating pancreatic neoplastic cells in a biological sample from a patient who has been determined to have pancreatic neoplastic cells comprising:
a) determining from the biological sample the levels of expression of a plurality of at least four miRNAs from the following group of biomarker miRNAs: miR-202-3p, miR-483-5p, miR-31-5p, miR-192-5p, miR-708-5p, miR-21-5p, miR-375, miR-210, miR-99a-5p, miR-485-3p, miR-10b-5p, miR-337-5p, and, miR-130b-3p; and,
b) calculating a risk score for the biological sample that identifies the sample as containing pancreatic cells that are characterized as mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof.
26 - 29 . (canceled)
30 . The method of claim 25 , wherein calculating a risk score comprises using a computer and an algorithm.
31 . The method of claim 25 , wherein calculating a risk score comprises applying model coefficients to each of the levels of expression.
32 . The method of claim 31 , wherein the model coefficients were determined using logistic regression modeling, linear discriminant analysis, quadratic discriminant analysis, neural network, support vector machine, k-nearest neighbor classifier, or a variation thereof.
33 - 43 . (canceled)
44 . The method of claim 25 , further comprising identifying the patient as having a risk score indicative of 50% chance or greater of having MCN.
45 . The method of claim 25 , further comprising identifying the patient as having a risk score indicative of 50% chance or greater of having IPMN.
46 . The method of claim 25 , further comprising identifying the patient as having a risk score indicative of 50% chance or greater of having PDAC.
47 . The method of claim 25 , further comprising identifying the patient as having a risk score indicative of 50% chance or greater of having SN.
48 - 83 . (canceled)
84 . A method for evaluating neoplastic pancreatic cells from a patient comprising:
a) measuring the level of expression in the neoplastic pancreatic cells of at least one of the following diff pair miRNAs: miR-10b-5p, miR-21-5p, miR-31-5p, miR-98, miR-125-3p, miR-130b-3p, miR-134, miR-135a-5p, miR-135b-5p, miR-192-5p, miR-194-5p, miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-202-3p, miR-203, miR-210, miR-224-5p, miR-323-3p, miR-337-5p, miR-345-5p, miR-363-3p, miR-379-5p, miR-382-5p, miR-429, miR-483-5p, miR-485-3p, miR-485-5p, miR-489, miR-708-5p, or miR-885-5p, wherein at least one of the miRNAs is a biomarker miRNA and one is a comparative miRNA;
b) determining at least one biomarker diff pair value based on the level of expression of the biomarker miRNA compared to the level of expression of the comparative miRNA; and,
c) determining whether the neoplastic pancreatic cells are mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof, based on the biomarker diff pair value(s).
85 - 88 . (canceled)
89 . The method of claim 84 , further comprising calculating a risk score comprises using a computer and an algorithm.
90 . The method of claim 84 , wherein calculating a risk score comprises applying model coefficients to each of the levels of expression.
91 . The method of claim 90 , wherein the model coefficients were determined using logistic regression modeling, linear discriminant analysis, quadratic discriminant analysis, neural network, support vector machine, k-nearest neighbor classifier, or a variation thereof.
92 - 98 . (canceled)
99 . The method of claim 84 , wherein the plurality of biomarkers miRNAs comprises miR-130b-3p, miR-192-59, miR-202-3p, and miR-337-5p.
100 . The method of claim 84 , wherein the plurality of biomarkers miRNAs comprises miR-10b-5p, miR-202-3p, miR-210, and miR-375.
101 . The method of claim 84 , wherein the plurality of biomarkers miRNAs comprises miR-31-5p, miR-99a-5p, miR-375, and miR-483-5p.
102 . The method of claim 84 , wherein the plurality of biomarkers miRNAs comprises miR-21-5p, miR-375, miR-485-3p, and miR-708-5p.
103 - 220 . (canceled)